RecruitingNCT04406831

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Sponsor

Nuvance Health

Enrollment

200 participants

Start Date

Apr 1, 2015

Study Type

OBSERVATIONAL

Conditions

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Stage IV Pancreatic Neoplasms Pancreatic Cancer Stage III

Summary

Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood samples and health data from patients with pancreatic cancer to look at tiny molecules in the blood called microRNAs. The goal is to find out whether certain patterns of these molecules can help doctors diagnose pancreatic cancer earlier, predict outcomes, or track how well treatment is working. **You may be eligible if...** - You have been diagnosed with pancreatic cancer (adenocarcinoma) confirmed by biopsy - Your cancer is inoperable (locally advanced or has spread) - You have measurable disease on scans - You are in reasonably good health (ECOG performance status 2 or less) - You have not yet received treatment for your metastatic pancreatic cancer **You may NOT be eligible if...** - You have already received treatment for metastatic pancreatic cancer - You are currently being treated for another active cancer at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBlood draw

Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw